Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

RVNC has been the subject of several other reports. Mizuho lowered their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Finally, Barclays dropped their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Revance Therapeutics presently has an average rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Stock Performance

Shares of NASDAQ RVNC opened at $3.65 on Wednesday. The firm has a fifty day simple moving average of $3.64 and a two-hundred day simple moving average of $4.19. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $6.65. The firm has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Institutional Investors Weigh In On Revance Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Natixis bought a new position in Revance Therapeutics in the 4th quarter worth about $31,000. Two Sigma Securities LLC purchased a new position in Revance Therapeutics in the fourth quarter worth about $35,000. Alpine Global Management LLC bought a new position in shares of Revance Therapeutics in the fourth quarter worth approximately $37,000. FORA Capital LLC purchased a new stake in shares of Revance Therapeutics during the third quarter valued at approximately $54,000. Finally, RPO LLC purchased a new stake in shares of Revance Therapeutics during the fourth quarter valued at approximately $55,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.